What is the effect of obicetrapid, a cholesterylester transfer protein inhibitor, in patients with ASCVD or heterozygous familial hypercholesterolemia? -
The BROADWAY trial (May 2025, n=2530) compared obicetrapid (at a dose of 10 mg daily for 365 days) to a matching placebo in adult patients with ASCVD or heterozygous familial hypercholesterolemia. The key exclusion criteria included NYHA class III or IV HF or LVEF < 30%, hospitalized for HF within 5 years, major adverse cardiac event within 3 months, uncontrolled severe hypertension, homozygous familial hypercholesterolemia, or active liver disease.
-
There was a significantly greater reduction in LDL-C level at day 84 (29.9% vs. -2.7%; MD 32.6, 95% CI 29.5 to 35.8, NNT=3). One of the secondary outcomes showed a significantly greater reduction in ApoB at day 365 (15.6% vs. 1.8%; MD 13.8, 95% CI 11.4 to 16.2) and a significantly greater improvement in HDL-C level at day 365 (125.4% vs. 3.4%; MD 122, 95% CI 117.5 to 126.6).
Conclusion: In adult patients with ASCVD or heterozygous familial hypercholesterolemia, obicetrapid was superior to placebo with respect to reduction in LDL-C level at day 84. You’ll find more of the latest studies relevant to primary care below. For a more comprehensive catalog of recent practice-changing trials, head over to Pathway! What is the effect of tirzepatide compared to semaglutide in patients with obesity? -
The SURMOUNT-5 trial (May 2025, n=750) compared tirzepatide (at a dose of 10 mg or 15 mg SC once weekly for 72 weeks) to semaglutide (at a dose of 1.7 mg or 2.4 mg SC once weekly for 72 weeks) in adult patients with obesity without T2DM. The key exclusion criteria included diabetes, previous or planned surgical treatment for obesity, treatment with a medication for weight reduction or a GLP-1 receptor agonist in the past 90 days, or a change in body weight of > 5 kg in the past 90 days.
- There was a significantly greater reduction in weight at week 72 (20.2% vs. 13.7%; MD 6.5, 95% CI 4.9 to 8.1, NNT=15). One of the secondary outcomes saw a significantly greater reduction in waist circumference at week 72 (18.4 cm vs. 13 cm; MD 5.4, 95% CI 3.6 to 7.1).
Conclusion: In adult patients with obesity without T2DM, tirzepatide was superior to semaglutide with respect to reduction in weight at week 72. What is the role of roflumilast foam in patients with psoriasis on the scalp and body? -
The ARRECTOR trial (May 2025, n=432) compared roflumilast foam (application of 3% emollient foam once daily for 8 weeks) to a matching placebo foam in patients, aged ≥ 12 years, with plaque psoriasis affecting up to 25% of the scalp and body. The key exclusion criteria included planned excessive exposure of treated areas to natural or artificial sunlight, tanning bed, or other LED, planned initiation or changes to concomitant medication that could affect psoriasis, current diagnosis of non-plaque forms of psoriasis or drug-induced psoriasis, or discontinuation of current psoriasis treatment is inadvisable.
- There was a significant increase in Scalp-Investigator Global Assessment success at week 8 (66.4% vs. 27.8%; AD 37.1%, 97.5% CI 25.7 to 48.6, NNT=2). There was also a significant increase in Body-Investigator Global Assessment success at week 8 (45.5% vs. 20.1%; AD 24.8%, 97.5% CI 13.6 to 36).
Conclusion: In patients aged ≥ 12 years with plaque psoriasis affecting up to 25% of the scalp and body, roflumilast foam was superior to vehicle foam with respect to a Scalp-Investigator Global Assessment success at week 8. Acknowledgements: - Editorial Team: Jeremy Swisher, MD, Cole Phillips, MD, Khudhur Moh, MD, Hovhannes Karapetyan, MD
|
|
|
